Navigation Links
Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Date:10/21/2010

ciatica."  

The merger agreement is subject to customary closing conditions.  Upon the closing of the merger, Cephalon would purchase all of the outstanding capital stock of BDC for $12.5 million, subject to net working capital and debt adjustments set forth in the merger agreement.  BDC already received $30 million for the Cephalon option to acquire BDC, and shareholders could receive additional payments related to regulatory and sales milestones.  BDC was advised on this transaction by Extera Partners.  

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world.  In total, Cephalon sells more than 150 products in nearly 100 countries.  More information on Cephalon and its products is available at www.cephalon.com.

About BioAssets Development CorporationBioAssets Development Corporation is a private company pioneering novel spine indications for emerging and marketed biologic drugs. The Company's lead initiative focuses on the development of a TNF inhibitor therapy to treat the underlying cause of pain in sciatica.  For more information, visit www.biodevco.com.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements.  Forward-looking statements provide Cephalon's curre
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... QC , May 5, 2015 /CNW Telbec/ - ... Laval and known under the ... today the closing of the transaction previously announced on ... the issued and outstanding  shares of Orthoconcept (2008) inc.   ... issuing 500 000 common shares (TSXV: ERG) to the ...
(Date:5/5/2015)... EXTON, Pa. , May 5, 2015  The ... global leader in pharmacokinetic testing of drugs and safety ... Gum , Associate Director of Preclinical Studies, presented at ... in Vision and Ophthalmology (ARVO) in Denver, ... presentation was "Safety Assessment of a Novel, Cross-Linked, Bio-Absorbable ...
(Date:5/5/2015)... NIJMEGEN, the Netherlands , May ... company developing lower esophageal sphincter (LES) stimulation therapy ... positive safety and efficacy results. The results demonstrated ... heartburn and regurgitation and the "gold-standard" esophageal acid ... near-complete elimination of dependence on daily PPI medications. ...
Breaking Medicine Technology:Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3
... (MARKET WIRE) -- July 06, ... <a target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or ... the European Patent,Office has granted ... with claims related to,oral vaccination ...
... in The Lancet on TMC125, an Investigational ... /PRNewswire/ -- Data from two,ongoing Phase 3 ... adult patients with documented non-nucleoside reverse,transcriptase inhibitor ... undetectable viral load (defined as achieving,confirmed undetectable ...
Cached Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 Private equity ... FZ LLC has announced that its dental stem cell ... Store-A-Tooth™ increased once again--in April, 2015 –and posted yet ... of increased record volume and represents a significant 54% ... dental stem cell biobank is conducted via the Store-A-Tooth ...
(Date:5/5/2015)... “Given that Hispanics are one in six people ... are a major step in the arsenal of facts documenting ... past 30 years, data have accumulated that the health of ... the urgency and the need to create new models of ... all,” said Jane L. Delgado, PhD, MS, President and CEO ...
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... The newly minted Regan Arts has just released a unique self-help ... from his 20 years working in the field of wilderness therapy. ... a parenting book and why this one, she replied, “What resonates ... it is a journey, not a destination...that the question is not ... together and sometimes not...that each of our struggles is unique. What ...
(Date:5/5/2015)... Skedans Systems a division ... the Skedans Sensor Collaboration Platform at AUVSI's Unmanned ... app developers, provides tooling to deliver real time information ... The Skedans Sensor Collaboration Platform is a single unified ... of Things, Web Real Time Communications (WebRTC), and commercial ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2
... patients with a devastating form of vasculitis who are in ... the disease flaring, according to a new study by investigators ... the first study to suggest that mental health is a ... disorders characterized by the inflammatory destruction of blood vessels. The ...
... Too few American doctors use oral food challenges to diagnose ... the gold standard, according to a new study. In ... if it causes an allergic reaction. This is done under ... identified 3,339 cases of food allergy. However, only 61.5 percent ...
... , SATURDAY, Nov. 5 (HealthDay News) -- Pregnancy ... study indicates. Lupus is a chronic inflammatory disease ... arthritis, fatigue and rashes. Lupus has been known to cause ... often emerging in their 20s and 30s when many women ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... test may not be accurate in identifying a gene that ... get. The Oncotype DX, marketed by Genomic Health, results ... to a study published Oct. 18 in the Journal ...
... Households Financial strain and competing priorities at ... readmissions of children with asthma from single-parent homes compared ... at the American College of Allergy, Asthma and Immunology ... The study, performed at Cincinnati Children,s Hospital Medical Center, ...
... , FRIDAY, Nov. 4 (HealthDay News) -- Online forums ... with their feelings of loss and isolation, according to a ... System found the women are often driven to the Internet ... or family. They noted that half of the women who ...
Cached Medicine News:Health News:Stress triggers disease flares in patients with vasculitis 2Health News:Stress triggers disease flares in patients with vasculitis 3Health News:'Food Challenges' Provide Best Allergy Diagnoses: Study 2Health News:Pregnancy Safe for Most Women With Lupus: Study 2Health News:Common Breast Cancer Gene Test May Be Flawed, Study Says 2Health News:Common Breast Cancer Gene Test May Be Flawed, Study Says 3Health News:New interventions, recommendations for controlling allergies & asthma in children 2Health News:New interventions, recommendations for controlling allergies & asthma in children 3Health News:New interventions, recommendations for controlling allergies & asthma in children 4Health News:New interventions, recommendations for controlling allergies & asthma in children 5Health News:Online Forums Can Help Women Cope With Pregnancy Loss 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: